Long Focus Capital Management, LLC Adaptimmune Therapeutics PLC Transaction History
Long Focus Capital Management, LLC
- $2.73 Billion
- Q3 2024
A detailed history of Long Focus Capital Management, LLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Long Focus Capital Management, LLC holds 13,299,890 shares of ADAP stock, worth $7.71 Million. This represents 0.46% of its overall portfolio holdings.
Number of Shares
13,299,890
Previous 12,346,417
7.72%
Holding current value
$7.71 Million
Previous $12.1 Million
4.42%
% of portfolio
0.46%
Previous 0.49%
Shares
13 transactions
Others Institutions Holding ADAP
# of Institutions
83Shares Held
150MCall Options Held
60.8KPut Options Held
5.8K-
Matrix Capital Management Company, LP Waltham, MA37.7MShares$21.9 Million1.71% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$15.9 Million1.13% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$9.91 Million1.24% of portfolio
-
Baillie Gifford & CO16.8MShares$9.73 Million0.01% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA10MShares$5.8 Million0.56% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $94.8M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...